Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2022-02-18 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
关于合作设立医药产业投资基金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Microchip Biotechnology Co., Ltd. regarding the cooperation to establish a pharmaceutical industry investment fund. It details the investment fund's structure, investment amounts, partners, management fees, investment scope, and associated risks. The document is a formal announcement about a capital investment activity, specifically the company's investment in a fund, including financial commitments and strategic rationale. It does not contain financial statements, quarterly or annual results, nor is it a transcript, audit report, or governance document. It is not a report publication announcement since it contains substantive information about the investment. The content fits best under Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes through investment in a fund.
2022-02-18 Chinese
关于向不特定对象发行可转换公司债券申请获得上海证券交易所科创板上市委员会审核通过的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the approval by the Shanghai Stock Exchange's Science and Technology Innovation Board Listing Committee for the company's application to issue convertible bonds to unspecified investors. It mentions the need to complete registration with the China Securities Regulatory Commission before implementation. The document is short (553 characters) and serves as a formal announcement of a financing activity rather than a detailed report or financial statement. Therefore, it fits the category of Capital/Financing Update (CAP).
2022-02-17 Chinese
安信证券股份有限公司关于深圳微芯生物科技股份有限公司向不特定对象发行可转换公司债券之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市保荐书" which translates to "Listing Sponsorship Letter" or "Sponsorship Document" related to the issuance of convertible bonds by Shenzhen Microchip Biotechnology Co., Ltd. It contains detailed information about the company, its business, financial data, risks related to the convertible bond issuance, and the role of the sponsoring securities firm. The document is a formal sponsorship report required for the issuance and listing of convertible bonds on the Shanghai Stock Exchange. It is not a financial report like an annual or interim report, nor is it a simple announcement or presentation. It is a detailed regulatory filing related to capital raising and securities issuance. Given the content and purpose, the document fits best under the category of Capital/Financing Update (CAP).
2022-01-25 Chinese
关于深圳微芯生物科技股份有限公司向不特定对象发行可转换公司债券审核中心意见落实函的回复
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from Shenzhen Microchip Biotechnology Co., Ltd. addressing the Shanghai Stock Exchange's review comments on the company's issuance of convertible bonds to unspecified investors. It discusses environmental impact assessment (EIA) approval progress, project risks, and includes statements from the company's chairman and the sponsoring institution's management. The document is regulatory in nature, responding to a regulatory authority's inquiry about a financing activity (convertible bond issuance). It is not a full financial report, earnings release, or management discussion. It is also not a simple announcement or a proxy statement. The document is a formal regulatory filing responding to a review letter, which fits best under Regulatory Filings (RNS). The document length is about 5,546 characters, which is substantive but does not contain financial statements or detailed financial analysis. Therefore, the classification is RNS with high confidence.
2022-01-25 Chinese
深圳微芯生物科技股份有限公司向不特定对象发行可转换公司债券募集说明书（上会稿）
Capital/Financing Update Classification · 95% confidence The document is titled '募集说明书' which translates to 'Offering Prospectus' or 'Offering Circular'. It is issued by Shenzhen Microchip Biotechnology Co., Ltd. and relates to the issuance of convertible corporate bonds to unspecified investors. The content includes detailed information about the bond issuance, risks, credit ratings, subscription commitments by shareholders and management, and regulatory compliance statements. This type of document is a detailed disclosure related to capital raising activities, specifically a bond issuance. It is not a general annual or quarterly report, nor is it a simple announcement or presentation. It fits the category of Capital/Financing Update (CAP) because it provides comprehensive information about the company's financing activity through convertible bond issuance.
2022-01-25 Chinese
安信证券股份有限公司关于深圳微芯生物科技股份有限公司向不特定对象发行可转换公司债券之发行保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" (Issuance Sponsorship Letter) for Shenzhen Microchip Biotechnology Co., Ltd. It is issued by a securities company (Anxin Securities) acting as the sponsor for the issuance of convertible corporate bonds to unspecified investors. The document contains detailed legal and regulatory compliance statements, due diligence confirmations, descriptions of the issuance terms, internal approval procedures, and the sponsor's commitment to the issuance. It is a formal sponsorship letter related to a capital raising activity involving convertible bonds. This type of document is not a financial report, earnings release, or management discussion, but rather a formal capital/financing update and issuance sponsorship document. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial and contains detailed issuance information, not just an announcement or a brief note, so it is not RPA or RNS.
2022-01-25 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.